Fig. 2
Expression levels of BTNL9 gene in THCA. (A) Gene tracks of BTN-specific enhancers (chr5:181,035,673–181,047,436; chr5:181,051,544–181,054,849). The adjacent gene BTNL9 showed much stronger signals in H3K27ac ChIP-seq and RNA-seq tracks in BTN tissues than PTC tissues. (B) The expression level of BTNL9 was significantly lower in THCA compared with normal samples based on TCGA and GTEx datasets. (C)BTNL9 expression in different cancer types from TCGA and GTEx datasets. (D) Decreased expression of BTNL9 in THCA compared with the matched normal tissues from TCGA datasets. (E) Higher level of BTNL9 transcription is associated with more favorable PFI in patients with THCA. Analysis was performed with TCGA (THCA) datasets. (F) Relative BTNL9 mRNA expression levels in 30 pairs of THCA and paired paracancerous tissues. Expression analysis was normalized against GAPDH. *p < 0.05, **p < 0.01, ***p < 0.001. THCA, thyroid carcinoma; PTC, papillary thyroid carcinoma; BTN, benign thyroid nodule; PFI, progress-free interval; TCGA, The Cancer Genome Atlas; GTEx, Genotype-Tissue Expression. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical and endocervical cancers; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma